The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

In this video, Maria Caterina Rotiroti, PhD, discusses notable presentations on chimeric antigen receptor T-cell therapy at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...